Caligan Partners LP: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1727492) · Explore on the interactive board
Caligan Partners LP disclosed 25 US equity positions worth $2.1bn in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is LQDA at 31.2% of the reported book, followed by RVMD, ABVX. The top ten holdings are 82.9% of the book, and the portfolio behaves like about 7 equal-weight positions. Versus the prior filing it opened 5 new positions, added to 9, reduced 3 and exited 4. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Caligan Partners LP own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 5 new, 9 added, 3 reduced, 4 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | LQDA LIQUIDIA CORPORATION | Healthcare | 31.2% | $647.3m | 8,118,892 | 0% | held |
| 2 | RVMD REVOLUTION MEDICINES INC | Healthcare | 17.7% | $367.4m | 1,961,795 | 19% | added |
| 3 | ABVX ABIVAX SA | Healthcare | 10.0% | $207.6m | 1,557,924 | 7% | added |
| 4 | PCVX VAXCYTE INC | Healthcare | 6.1% | $127.2m | 2,188,636 | 6% | added |
| 5 | EXEL EXELIXIS INC | Healthcare | 4.1% | $84.5m | 1,553,262 | 0% | held |
| 6 | TNGX TANGO THERAPEUTICS INC | Healthcare | 3.8% | $78.2m | 2,500,103 | 4% | added |
| 7 | AVTX AVALO THERAPEUTICS INC | Healthcare | 2.8% | $58.5m | 3,163,866 | 94% | added |
| 8 | XENE XENON PHARMACEUTICALS INC | Healthcare | 2.6% | $53.7m | 889,944 | -36% | reduced |
| 9 | ADMA ADMA BIOLOGICS INC | Healthcare | 2.3% | $47.9m | 5,725,007 | 20% | added |
| 10 | LB PHARMACEUTICALS INC | 2.3% | $46.7m | 1,438,070 | 0% | held | |
| 11 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 2.1% | $43.9m | 1,381,317 | – | new |
| 12 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 1.9% | $40.3m | 2,193,981 | – | new |
| 13 | VOR VOR BIOPHARMA INC | Healthcare | 1.7% | $35.4m | 1,925,066 | 0% | held |
| 14 | SABS SAB BIOTHERAPEUTICS INC | 1.5% | $31.1m | 7,967,207 | 0% | held | |
| 15 | IVA INVENTIVA SA | 1.5% | $30.9m | 8,163,191 | 64% | added | |
| 16 | AURA AURA BIOSCIENCES INC | 1.5% | $30.5m | 4,298,248 | 1770% | added | |
| 17 | TYRA TYRA BIOSCIENCES INC | Healthcare | 1.2% | $25.8m | 806,986 | -37% | reduced |
| 18 | IRD OPUS GENETICS INC | 1.2% | $25.0m | 6,077,084 | 0% | held | |
| 19 | ANIK ANIKA THERAPEUTICS INC | Healthcare | 1.0% | $21.0m | 1,435,130 | 0% | held |
| 20 | SGMT SAGIMET BIOSCIENCES INC | Healthcare | 0.9% | $19.3m | 2,500,000 | – | new |
| 21 | ARTV ARTIVA BIOTHERAPEUTICS INC | 0.8% | $16.8m | 1,736,111 | – | new | |
| 22 | FTH FAETH THERAPEUTICS INC | 0.8% | $15.7m | 629,467 | 400% | added | |
| 23 | MBX MBX BIOSCIENCES INC | Healthcare | 0.5% | $11.0m | 200,000 | -76% | reduced |
| 24 | VRCA VERRICA PHARMACEUTICALS INC | 0.3% | $5.7m | 923,910 | 0% | held | |
| 25 | CLRB CELLECTAR BIOSCIENCES INC | 0.1% | $1.3m | 469,998 | – | new |
What did Caligan Partners LP sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| MLYS MINERALYS THERAPEUTICS INC | 54.2% | $75.1m |
| SYRE SPYRE THERAPEUTICS INC | 31.9% | $44.3m |
| MAZE MAZE THERAPEUTICS INC | 13.2% | $18.4m |
| XLO XILIO THERAPEUTICS INC | 0.7% | $943.0k |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 90.2% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Caligan Partners LP's portfolio?
Across every quarter Caligan Partners LP has filed, its median largest position is 26.5% of the book and its median top-ten weight is 80.9%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 4.0 completed holding spells, the median lasted 1.0 quarters; 25.0 positions are still open and their final length is unknown.